AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8527550 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated uniforms
Number of subjects: 229
Study 8527550 — intervention group
Group type: COMPARATOR
Intervention: Control uniforms (washed in water)
Number of subjects: 229
Study 8527550 — intervention group
Group type: COMPARATOR
Intervention: Control uniforms (not impregnated)
Number of subjects: 229
Study 1983106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol
Number of subjects: 40
Study 1983106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% metipranolol
Number of subjects: 40
Study 1983106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7027750 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose of glipizide (5 mg p.o.)
Number of subjects: 13
Study 7027750 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with glipizide (range 7.5‐20 mg, mean 10.4 mg)
Number of subjects: 13
Study 7027750 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose regime
Number of subjects: 13
Study 7027750 — intervention group
Group type: COMPARATOR
Intervention: Three-part divided dose regime
Number of subjects: 13
Study 7027750 — intervention group
Group type: COMPARATOR
Intervention: Single dose and divided dose regimes
Number of subjects: 13
Study 7027750 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 13
Study 31634870 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg every 8 hours for 7 days
Number of subjects: 80
Study 31634870 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard treatments
Number of subjects: 80
Study 31634870 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin group
Number of subjects: 80
Study 31043521 — intervention group
Group type: EXPERIMENTAL
Intervention: Balovaptan 4 mg
Number of subjects: 223
Study 31043521 — intervention group
Group type: EXPERIMENTAL
Intervention: Balovaptan 10 mg
Number of subjects: 223
Study 31043521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 28422628 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching for stroke survivors (OPC‐Stroke)
Number of subjects: 21
Study 28422628 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study 25482469 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of 20 mL bupivacaine 0.25%
Number of subjects: 357
Study 25482469 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (20 mL saline 0.9%)
Number of subjects: 357
Study 25482469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine vs saline)
Number of subjects: 357
Study 24494521 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium Elastic Nails (TEN)
Number of subjects: 30
Study 24494521 — intervention group
Group type: COMPARATOR
Intervention: Traction with spica casting
Number of subjects: 30
Study 24494521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 21342412 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg + Metformin 500 mg
Number of subjects: 1306
Study 21342412 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg + Metformin 500 mg
Number of subjects: 1306
Study 21342412 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin 10 mg
Number of subjects: 1306
Study 21342412 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 1306
Study 21342412 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Number of subjects: 1306
Study 21342412 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1306
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.08%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.10%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.12%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.14%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.16%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.18%
Number of subjects: 60
Study 19087002 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 60
Study 18245399 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental care (incubator covers and positioning aids)
Number of subjects: 179
Study 18245399 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care, no covers or nests)
Number of subjects: 179
Study 18245399 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 179
Study 16131291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation acupressure treatment
Number of subjects: 0
Study 16131291 — intervention group
Group type: COMPARATOR
Intervention: Relaxation acupressure treatment
Number of subjects: 0
Study 12383985 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172
Number of subjects: 760
Study 12383985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 10022558 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (5x6 eccentric muscle actions at 100 and 120% of one maximal repetition (IRM) for 21 sessions over 7 weeks)
Number of subjects: 17
Study 10022558 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 17
Study 7759725 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 1012
Study 7759725 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary angioplasty
Number of subjects: 1012
Study 2107214 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 19
Study 2107214 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 19
Study 7360548 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information about the sensory capacity of neonates
Number of subjects: 40
Study 7360548 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional postpartum contact with their infants
Number of subjects: 40
Study 7360548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7360548 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 19 years and older
Number of subjects: 40
Study 7360548 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 18 years and younger
Number of subjects: 40
Study 29182415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammer Cycle Ergometer
Number of subjects: 11
Study 26869311 — intervention group
Group type: EXPERIMENTAL
Intervention: High irrigation pressure (200 mm Hg)
Number of subjects: 90
Study 26869311 — intervention group
Group type: COMPARATOR
Intervention: Low irrigation pressure (80 mm Hg)
Number of subjects: 90
Study 23981104 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg (one to three times daily)
Number of subjects: 390
Study 23981104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 22252545 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 12 months
Number of subjects: 69
Study 20157016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and telephone intervention consisting of mailings, telephone calls, and counseling (if requested or appropriate given a woman's genetic risk for breast cancer)
Number of subjects: 0
Study 20157016 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 0
Study 18548841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.2 mL injection)
Number of subjects: 14
Study 18548841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffered isotonic saline, 155 mmol/L)
Number of subjects: 14
Study 16800990 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuye Decoction (WYD)
Number of subjects: 82
Study 16800990 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific medicine)
Number of subjects: 82
Study 16800990 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group C)
Number of subjects: 82
Study 12548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 214
Study 12548305 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 214
Study 12548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 214
Study 10550755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 20 mg twice a day
Number of subjects: 439
Study 10550755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice a day
Number of subjects: 439
Study 10550755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg twice a day
Number of subjects: 439
Study 10550755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg twice a day
Number of subjects: 439
Study 10550755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 8983283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 111
Study 8983283 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 111
Study 8983283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and/or Imipenem
Number of subjects: 111
Study 1955603 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital condition (vaginal and anal examination)
Number of subjects: 72
Study 1955603 — intervention group
Group type: COMPARATOR
Intervention: Nongenital condition (scoliosis examination)
Number of subjects: 72
Study 7318355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7318355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 20
Study 30684769 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of 29 evidence-based nursing recommendations for conservative management of UI
Number of subjects: 381
Study 27993287 — intervention group
Group type: EXPERIMENTAL
Intervention: rehabilitation plus B12 group
Number of subjects: 32
Study 27993287 — intervention group
Group type: EXPERIMENTAL
Intervention: B12 group
Number of subjects: 32
Study 27993287 — intervention group
Group type: COMPARATOR
Intervention: rehabilitation group
Number of subjects: 32
Study 27993287 — intervention group
Group type: COMPARATOR
Intervention: placebo group
Number of subjects: 32
Study 24285576 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) for the first 6 weeks (group 1)
Number of subjects: 31
Study 24285576 — intervention group
Group type: COMPARATOR
Intervention: Penile vibratory stimulation (PVS) for the final 6 weeks (group 2)
Number of subjects: 31
Study 24285576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis after PVS
Number of subjects: 31
Study 24285576 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptom scores
Number of subjects: 31
Study 24285576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-limiting side effects
Number of subjects: 31
Study 24053900 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + SM + Ex
Number of subjects: 15
Study 24053900 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + SM
Number of subjects: 15
Study 24053900 — intervention group
Group type: COMPARATOR
Intervention: ST
Number of subjects: 15
Study 21338898 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental reproductive health (RH) knowledge
Number of subjects: 185
Study 21338898 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental comfort of communication
Number of subjects: 185
Study 21338898 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of talk
Number of subjects: 185
Study 21338898 — intervention group
Group type: COMPARATOR
Intervention: Parents' discordant perceptions regarding their child's reported involvement in relationships
Number of subjects: 185
Study 19240944 — intervention group
Group type: EXPERIMENTAL
Intervention: Yondelis (trabectedin, ET-743)
Number of subjects: 0
Study 17317021 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg ghrelin
Number of subjects: 12
Study 17317021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15054370 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0
Study 15054370 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 0
Study 11760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologist-led preventive intervention
Number of subjects: 489
Study 11760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led preventive intervention
Number of subjects: 489
Study 11760616 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard curriculum) with monitoring
Number of subjects: 489
Study 9479614 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-fenfluramine (FEN) 60 mg
Number of subjects: 17
Study 9479614 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium
Number of subjects: 17
Study 9479614 — intervention group
Group type: EXPERIMENTAL
Intervention: carbamazepine
Number of subjects: 17
Study 9479614 — intervention group
Group type: EXPERIMENTAL
Intervention: drug-free unipolar patients
Number of subjects: 17
Study 9479614 — intervention group
Group type: COMPARATOR
Intervention: nonresponders
Number of subjects: 17
Study 7524593 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor plasma concentrate 3000 U i.v.
Number of subjects: 40
Study 7524593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 3555690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg b.d. for 48 h pre-operatively and dipyridamole 200 mg b.d. with aspirin 300 mg daily for 6 weeks after surgery
Number of subjects: 148
Study 3555690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic dipyridamole and aspirin group
Number of subjects: 148
Study 3555690 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic control group
Number of subjects: 148
Study 3555690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin group
Number of subjects: 148
Study 3555690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 30753323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew nut phase (1.5 servings or 42 g of cashews/day)
Number of subjects: 42
Study 30753323 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no additions to the base diet)
Number of subjects: 42
Study 29102979 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg once daily
Number of subjects: 121
Study 29102979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 25232958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 1% Chamomilla recutita extract
Number of subjects: 40
Study 25232958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 0.5% and 2% Chamomilla recutita extract
Number of subjects: 40
Study 25232958 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 40
Study 23051876 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterostomal nurse telephone follow-up (2-3 calls during follow-up period)
Number of subjects: 103
Study 23051876 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge care (control group)
Number of subjects: 103
Study 22097346 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen-restoring decoction combined with dormancy hygiene education (A group)
Number of subjects: 107
Study 22097346 — intervention group
Group type: COMPARATOR
Intervention: Spleen-restoring decoction alone (B group)
Number of subjects: 107
Study 22097346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (A and B groups)
Number of subjects: 107
Study 20015430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel thread-drawing therapy
Number of subjects: 68
Study 20015430 — intervention group
Group type: COMPARATOR
Intervention: Multiple incisions and drainage (Control)
Number of subjects: 68
Study 17047542 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy, Exercise, and Walking Group
Number of subjects: 58
Study 17047542 — intervention group
Group type: COMPARATOR
Intervention: Flexion Exercise and Walking Group
Number of subjects: 58
Study 15008862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromated glycerin (CG)
Number of subjects: 150
Study 15008862 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (POL) 0.25% solution
Number of subjects: 150
Study 15008862 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (POL) 0.25% foam
Number of subjects: 150
Study 11489037 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized double-blind clinical trial (RDBCT)
Number of subjects: 0
Study 11489037 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and accounting for experimenter beliefs and expectations
Number of subjects: 0
Study 9215605 — intervention group
Group type: EXPERIMENTAL
Intervention: Itasetron hydrochloride (0.5, 1, 2, 4, and 8 mg twice daily)
Number of subjects: 104
Study 9215605 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg twice daily)
Number of subjects: 104
Study 9215605 — intervention group
Group type: EXPERIMENTAL
Intervention: Itasetron hydrochloride
Number of subjects: 104
Study 9215605 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 104
Study 7977542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal smoking cessation interventions
Number of subjects: 11
Study 3301986 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW) immunotherapy, 15 weekly injections totaling 1359 allergy units
Number of subjects: 81
Study 3301986 — intervention group
Group type: COMPARATOR
Intervention: Caramelized glucose histamine placebo
Number of subjects: 81
Study 3301986 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW) immunotherapy
Number of subjects: 81
Study 29608659 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 461
Study 29608659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 27272893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-sylvian SAH
Number of subjects: 48
Study 27272893 — intervention group
Group type: COMPARATOR
Intervention: Temporobasal SAH
Number of subjects: 48
Study 27272893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 24631977 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic conversation during driving under lorazepam
Number of subjects: 16
Study 24631977 — intervention group
Group type: EXPERIMENTAL
Intervention: No conversation during driving under lorazepam
Number of subjects: 16
Study 24631977 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition with no conversation
Number of subjects: 16
Study 24631977 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of driving performance before the drive
Number of subjects: 16
Study 24631977 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of driving performance during or after the drive
Number of subjects: 16
Study 22198971 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit religion priming
Number of subjects: 0
Study 22198971 — intervention group
Group type: COMPARATOR
Intervention: No religion priming
Number of subjects: 0
Study 19368912 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU of rFSH (group A)
Number of subjects: 119
Study 19368912 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 IU of rFSH (group B)
Number of subjects: 119
Study 19368912 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of rFSH (group C)
Number of subjects: 119
Study 18705320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO), started 3 days after operation
Number of subjects: 14
Study 18705320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBO treatment)
Number of subjects: 14
Study 17286120 — intervention group
Group type: EXPERIMENTAL
Intervention: Blurred natural scenes
Number of subjects: 0
Study 17286120 — intervention group
Group type: EXPERIMENTAL
Intervention: Local motion information
Number of subjects: 0
Study 12831383 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care buprenorphine treatment
Number of subjects: 115
Study 12831383 — intervention group
Group type: COMPARATOR
Intervention: Specialist clinic buprenorphine treatment
Number of subjects: 115
Study 12831383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study 11573756 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM nutrient database
Number of subjects: 42
Study 11573756 — intervention group
Group type: COMPARATOR
Intervention: Food record booklet
Number of subjects: 42
Study 8156354 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg every 8 h
Number of subjects: 252
Study 8156354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 2901251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 12
Study 2901251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 12
Study 2901251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30419125 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 27
Study 30419125 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 27
Study 28541887 — intervention group
Group type: EXPERIMENTAL
Intervention: videos with text messages
Number of subjects: 90
Study 28541887 — intervention group
Group type: EXPERIMENTAL
Intervention: videos only
Number of subjects: 90
Study 28541887 — intervention group
Group type: EXPERIMENTAL
Intervention: text messages-only
Number of subjects: 90
Study 28541887 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 90
Study 26255876 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for excessive gingival exposure by septum cartilage reinforcement and additional extension using an autologous cartilage graft or ePTFE implant.
Number of subjects: 121